J. G. Gribben, N. Fowler, and F. Morschhauser, Mechanisms of action of lenalidomide in B-cell non-hodgkin lymphoma, J Clin Oncol, vol.33, issue.25, pp.2803-2811, 2015.

F. J. Hernandez-ilizaliturri, N. Reddy, B. Holkova, E. Ottman, and M. S. Czuczman,

, Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model, Clin Cancer Res, vol.11, issue.16, pp.5984-5992, 2005.

L. Wu, M. Adams, and T. Carter, lenalidomide enhances natural killer cell and monocytemediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells, Clin Cancer Res, vol.14, issue.14, pp.4650-4657, 2008.

N. Reddy, F. J. Hernandez-ilizaliturri, and G. Deeb, Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo, Br J Haematol, vol.140, issue.1, pp.36-45, 2008.

L. Zhang, Z. Qian, and Z. Cai, Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo, Am J Hematol, vol.84, issue.9, pp.553-559, 2009.

N. H. Fowler, R. E. Davis, and S. Rawal, Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial, Lancet Oncol, vol.15, issue.12, pp.1311-1318, 2014.

P. Martin, S. H. Jung, and B. Pitcher, A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance), Ann Oncol, vol.28, issue.11, pp.2806-2812, 2017.

J. Ruan, P. Martin, and B. Shah, Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma, N Engl J Med, vol.373, pp.1835-1844, 2015.

J. P. Leonard, S. H. Jung, and J. Johnson, Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (alliance), J Clin Oncol, vol.33, issue.31, pp.3635-3640, 2015.

M. Wang, N. Fowler, and N. Wagner-bartak, Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial, Leukemia, vol.27, issue.9, pp.1902-1909, 2013.

M. Wang, L. Fayad, and N. Wagner-bartak, Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial, Lancet Oncol, vol.13, issue.7, pp.716-723, 2012.

G. Niederfellner, A. Lammens, and O. Mundigl, Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies, Blood, vol.118, issue.2, pp.358-367, 2011.

E. Mossner, P. Brunker, and S. Moser, Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity, Blood, vol.115, issue.22, pp.4393-4402, 2010.

D. J. Kern, B. R. James, S. Blackwell, C. Gassner, C. Klein et al., GA101 induces NK